Chlamydia pneumoniae infection and coronary heart diseaseBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7121.1538 (Published 06 December 1997) Cite this as: BMJ 1997;315:1538
Trials should assess whether antibiotics eliminate organism from atherosclerotic lesions
- David Taylor-Robinson, Emeritus professora
- a Department of Genitourinary Medicine and Communicable Diseases, Imperial College School of Medicine at St Mary's, London W2 1NY
- b Department of Paediatrics, Sapporo Medical University, School of Medicine, Sapporo, Japan
- c Finchley Memorial Hospital, London N12 0JE
Editor—Gupta and Camm put the case for Chlamydia pneumoniae being involved in atherogenesis and outline possible mechanisms.1 As they point out, it is nearly 10 years since C pneumoniae was linked serologically with coronary heart disease. Interest might have waned but for Shor's observation, which was followed by international collaboration.2 Shor was the first to suspect the existence of C pneumoniae in the wall of atheromatous coronary arteries. Although some have disagreed,3 the cumulative observations of other workers leave no doubt that C pneumoniae often occurs in atheromatous coronary and other large arteries, sometimes in a viable form,4 and significantly less often in normal vessels.
As Gupta and Camm indicate, however, whether C pneumoniae initiates disease or invades after atherosclerosis has begun is unknown. If the latter, then whether it behaves as a bystander or potentiates chronic disease is also unknown. The possibility of a primary role might be looked at best by studies of early lesions in young people and by observations in animal models. Since C pneumoniae is sensitive to several antibiotics, the desire to set up extensive placebo controlled trials to help to determine …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial